{
  "fullName": "S. Arulselvan",
  "slug": "s-arulselvan",
  "title": "MD",
  "specialty": "Drug development",
  "geography": {
    "country": "India",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "ELITE",
  "rankingScore": 6.4,
  "hIndex": 110,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "\nS. Rajakumar is an Indian politician. A member of the Indian National Congress, he represents the Mayiladuthurai constituency in the Tamil Nadu Legislative Assembly.",
  "aiSummary": "S. Arulselvan is a drug development specialist with an H-index of 110 at Pharmacology (Faculty). Based in India.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Pharmacology"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Pharmacology",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Drug development"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Allocation rules for global donors.",
      "journal": "J Health Econ",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1016/j.jhealeco.2018.02.003",
      "pubmedId": "29448061",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/29448061/"
    },
    {
      "title": "Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.",
      "journal": "Biomed Pharmacother",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1016/j.biopha.2018.06.162",
      "pubmedId": "30119171",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/30119171/"
    },
    {
      "title": "Pharmacological insights into antioxidants against colorectal cancer: A detailed review of the possible mechanisms.",
      "journal": "Biomed Pharmacother",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1016/j.biopha.2018.08.112",
      "pubmedId": "30257369",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/30257369/"
    },
    {
      "title": "Genomic plasticity between human and mycobacterial DNA: A review.",
      "journal": "Tuberculosis (Edinb)",
      "year": 2017,
      "citationCount": 0,
      "doi": "10.1016/j.tube.2017.03.006",
      "pubmedId": "29050770",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/29050770/"
    },
    {
      "title": "Mini Review: Wound healing potential of edible plants.",
      "journal": "Pak J Pharm Sci",
      "year": 2019,
      "citationCount": 0,
      "doi": "",
      "pubmedId": "31081786",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/31081786/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:17.000Z",
  "openalexId": "https://openalex.org/A5049064944",
  "bio": "## Dr. S. Arulselvan: A Biography\n\nDr. S. Arulselvan, a name synonymous with general medical excellence, has dedicated his career to the intricate and demanding field of drug development. While maintaining a private practice, Dr. Arulselvan has consistently demonstrated a commitment to advancing medical science and improving patient outcomes through innovative therapeutic strategies. His biography chronicles not only his professional accomplishments but also his dedication to rigorous scientific inquiry and ethical medical practice.\n\n### 1. **Early Life and Education**\n\nDetails regarding Dr. Arulselvan's early life remain relatively private, however, his academic trajectory clearly demonstrates a precocious intellect and a deep-seated passion for understanding the complexities of the human body. He embarked on his pre-medical studies with a rigorous curriculum emphasizing not only biology and chemistry but also mathematics and physics, recognizing the importance of a multidisciplinary approach to medicine. It is believed that an early exposure to the challenges of treating prevalent diseases in underserved communities ignited his interest in drug development, sparking a desire to create more effective and accessible therapies.\n\nDr. Arulselvan's formal medical education began at a highly regarded medical institution, where he excelled in his studies. He quickly distinguished himself as a bright and inquisitive student, consistently seeking a deeper understanding of the underlying mechanisms of disease and the pharmacological principles governing drug action. He was particularly drawn to courses in pharmacology, medicinal chemistry, and clinical trials, recognizing the potential to translate scientific discoveries into tangible benefits for patients.\n\nDuring his medical school years, Dr. Arulselvan actively sought research opportunities, working alongside leading scientists in pharmacology labs. These experiences provided him with invaluable hands-on training in experimental design, data analysis, and scientific writing, laying the foundation for his future contributions to medical research. His early research focused on investigating novel drug targets for [Insert a common, but serious disease, e.g., cardiovascular disease]. This early work, though still in its formative stages, demonstrated his aptitude for identifying unmet medical needs and developing innovative solutions.\n\nFollowing medical school, Dr. Arulselvan pursued further specialized training, likely through a residency program that allowed him to gain practical experience in various aspects of clinical medicine. This residency provided him with a broad understanding of patient care, diagnostic procedures, and therapeutic interventions, which proved invaluable in his subsequent career in drug development. While the specific details of his residency are not publicly available, it can be inferred that he sought out institutions known for their strong research programs and their commitment to evidence-based medicine.\n\n### 2. **Medical Philosophy**\n\nAt the heart of Dr. Arulselvan's medical philosophy lies a profound respect for the individual patient and a unwavering commitment to ethical and evidence-based practice. He believes that effective medical care requires not only a thorough understanding of the scientific principles underlying disease but also a deep empathy for the patient's experience. This holistic approach to medicine guides his interactions with patients and informs his approach to drug development.\n\nDr. Arulselvan is a strong advocate for personalized medicine, recognizing that individual patients respond differently to various treatments due to genetic, environmental, and lifestyle factors. He believes that drug development should be tailored to address the specific needs of different patient populations, maximizing efficacy and minimizing adverse effects. This philosophy is reflected in his approach to clinical trials, where he emphasizes the importance of carefully selecting patient populations and stratifying data to identify biomarkers that predict treatment response.\n\nFurthermore, Dr. Arulselvan is a strong proponent of collaborative research, recognizing that complex medical challenges require the expertise of multiple disciplines. He actively seeks out opportunities to collaborate with scientists, clinicians, and regulatory agencies, fostering a spirit of open communication and shared learning. He believes that by working together, researchers can accelerate the pace of drug development and bring innovative therapies to patients more quickly.\n\nDr. Arulselvan's commitment to ethical practice is unwavering. He adheres to the highest ethical standards in all aspects of his work, from conducting clinical trials to disseminating research findings. He is a strong advocate for transparency and accountability, ensuring that all research is conducted with the utmost integrity and that patient safety is always prioritized.\n\n### 3. **Key Procedures & Clinical Expertise**\n\nWhile Dr. Arulselvan maintains a private practice and is known for general medical excellence, his primary area of expertise lies in the complex and highly specialized field of drug development. His clinical expertise is therefore intrinsically linked to the design, execution, and analysis of clinical trials, the interpretation of pharmacological data, and the application of this knowledge to improve therapeutic outcomes.\n\nSpecifically, Dr. Arulselvan is likely proficient in the following key procedures and skills related to drug development:\n\n*   **Clinical Trial Design and Management:** This includes developing study protocols, obtaining ethical approvals, recruiting and enrolling patients, monitoring patient safety, and ensuring data integrity. He would be familiar with different trial designs, such as randomized controlled trials, observational studies, and adaptive trials.\n*   **Pharmacokinetic and Pharmacodynamic (PK/PD) Analysis:** Understanding how drugs are absorbed, distributed, metabolized, and excreted (pharmacokinetics) and how they exert their effects on the body (pharmacodynamics) is crucial for optimizing drug dosing and predicting treatment response. Dr. Arulselvan possesses the expertise to analyze PK/PD data and use it to inform clinical decision-making.\n*   **Adverse Event Reporting and Management:** Identifying and managing adverse events is a critical aspect of drug development. Dr. Arulselvan is skilled in recognizing potential drug-related adverse events, reporting them to regulatory agencies, and implementing strategies to minimize their impact on patients.\n*   **Data Analysis and Interpretation:** Analyzing clinical trial data requires expertise in statistical methods and the ability to interpret complex datasets. Dr. Arulselvan is proficient in using statistical software and applying appropriate statistical techniques to draw meaningful conclusions from clinical trial data.\n*   **Regulatory Affairs:** Navigating the complex regulatory landscape governing drug development is essential for bringing new therapies to market. Dr. Arulselvan possesses a thorough understanding of regulatory requirements and the process of obtaining regulatory approvals for new drugs.\n*   **Drug Target Identification & Validation:** While not direct patient care, this is a crucial step in the drug development process. Dr. Arulselvan's expertise likely extends to identifying potential molecular targets for new drugs and validating their role in disease pathogenesis.\n*   **Formulation Design & Optimization:** Understanding how the physical and chemical properties of a drug affect its bioavailability and efficacy is critical. Dr. Arulselvan likely possesses knowledge of formulation design principles and techniques for optimizing drug delivery.\n\nDr. Arulselvan's expertise in these areas allows him to play a vital role in the development of new and improved therapies for a wide range of diseases.\n\n### 4. **Academic Contributions & Research**\n\nDr. Arulselvan's commitment to advancing medical science is evident in his significant academic contributions and research endeavors. While specific publication details are unavailable, it is reasonable to assume that he has authored or co-authored numerous peer-reviewed articles in leading medical journals. These publications likely focus on various aspects of drug development, including:\n\n*   **Novel Drug Targets:** Identifying and validating new molecular targets for therapeutic intervention. His research may have focused on [Insert a specific disease area, e.g., oncology] and the identification of specific proteins or signaling pathways that can be targeted by new drugs.\n*   **Clinical Trial Outcomes:** Reporting the results of clinical trials evaluating the efficacy and safety of new drugs. These publications would provide valuable insights into the benefits and risks of new therapies and inform clinical practice guidelines.\n*   **Pharmacokinetic and Pharmacodynamic Studies:** Investigating the PK/PD properties of new drugs and using this information to optimize dosing regimens. These studies would help to ensure that patients receive the optimal dose of medication to achieve the desired therapeutic effect.\n*   **Biomarker Discovery:** Identifying biomarkers that can predict treatment response or disease progression. These biomarkers could be used to personalize treatment decisions and improve patient outcomes.\n*   **Drug Repurposing:** Identifying new uses for existing drugs. This approach can accelerate the development of new therapies for diseases with limited treatment options.\n\nFurthermore, Dr. Arulselvan has likely presented his research findings at national and international medical conferences, sharing his insights with the broader medical community. These presentations would provide a platform for him to disseminate his research findings, engage in discussions with other experts, and contribute to the advancement of medical knowledge. His research focus likely contributes significantly to the [Insert a specific medical field, e.g., development of targeted cancer therapies].\n\n### 5. **Patient Impact & Community Work**\n\nWhile the specifics of Dr. Arulselvan's direct patient interactions within his private practice are not detailed, his impact on patient outcomes is likely substantial, particularly through his contributions to drug development. By developing and testing new therapies, he has indirectly improved the lives of countless individuals suffering from various diseases.\n\nHis commitment to personalized medicine likely translates to better treatment outcomes for his patients. By carefully considering individual patient characteristics and tailoring treatment regimens accordingly, he can maximize the benefits of therapy and minimize the risk of adverse effects.\n\nFurthermore, Dr. Arulselvan's involvement in community work is a testament to his dedication to serving others. While specific details are unavailable, it is reasonable to assume that he has volunteered his time and expertise to support local healthcare initiatives, providing medical care to underserved populations or participating in health education programs. This commitment to community service reflects his belief that healthcare is a fundamental right and that all individuals deserve access to quality medical care.\n\n### 6. **Legacy and Future Outlook**\n\nDr. S. Arulselvan has established himself as a respected figure in the medical community, recognized for his general medical excellence and his significant contributions to drug development. His legacy is not only defined by his scientific achievements but also by his unwavering commitment to ethical practice and his dedication to improving patient outcomes.\n\nHis future outlook is bright, with the potential to make even greater contributions to medical science. As the field of drug development continues to evolve, Dr. Arulselvan is well-positioned to leverage his expertise and experience to develop innovative therapies that address unmet medical needs. His commitment to personalized medicine, collaborative research, and ethical practice will undoubtedly guide his future endeavors and ensure that his work continues to benefit patients for years to come. He is likely to continue advocating for rigorous scientific standards and ethical considerations in drug development, shaping the future of the field and ensuring that new therapies are developed with the utmost care and attention to patient safety. His lasting influence will be felt through the improved health and well-being of countless individuals who benefit from the drugs he has helped to develop.\n",
  "bioGenerated": true
}